Key result
Telmisartan reverses LV remodeling and increases serum adiponectin vs amlodipine in essential hypertension.
Why the study?
Does telmisartan improve serum adiponectin levels and left ventricular remodeling in patients with essential hypertension complicated with left ventricular hypertrophy compared to amlodipine?
Population
240 patients with essential hypertension complicated with left ventricular hypertrophy, mean age 62.2, 60%…
Comparison
Telmisartan 40 mg orally once daily for 12 weeks vs Amlodipine 5 mg orally once daily for 12 weeks
Design
RCT, Randomly divided
Follow-up
12 weeks
Authors
Loading...
May support telmisartan preference in hypertensive LVH; extends RCT evidence for ARB effects on adiponectin and remodeling.
RCT (n=240)
Randomly divided
No
Does telmisartan improve serum adiponectin levels and left ventricular remodeling in patients with essential hypertension complicated with left ventricular hypertrophy compared to amlodipine?
Absolute Event Rate: 110% vs 130.76%
p-value: p=<0.01
Telmisartan, but not amlodipine, significantly increases serum adiponectin levels and reverses left ventricular remodeling in patients with essential hypertension and left ventricular hypertrophy.
Lin et al. (2018) conducted an RCT in Essential hypertension complicated with left ventricular hypertrophy (n=240). Telmisartan vs. Amlodipine (5 mg once daily) was evaluated on Left Ventricular Mass Index (LVMI) at 12 weeks (p=<0.01). Compared with amlodipine, 12 weeks of telmisartan treatment significantly increased serum adiponectin levels and reversed left ventricular remodeling in patients with essential hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: